# A Phase III Study of KN026 in Combination With HB1801 as Adjuvant Therapy for Resectable HER2-Positive Breast Cancer

> **NCT07441460** · PHASE3 · RECRUITING · sponsor: **Shanghai JMT-Bio Inc.** · enrollment: 1800 (estimated)

## Conditions studied

- Resectable HER2-positive Breast Cancer

## Interventions

- **DRUG:** KN026
- **DRUG:** HB1801
- **DRUG:** Trastuzumab
- **DRUG:** Pertuzumab
- **DRUG:** Docetaxel
- **DRUG:** Epirubicin
- **DRUG:** Doxorubicin
- **DRUG:** Cyclophosphamide
- **DRUG:** Carboplatin

## Key facts

- **NCT ID:** NCT07441460
- **Lead sponsor:** Shanghai JMT-Bio Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-03-06
- **Primary completion:** 2034-08-07
- **Final completion:** 2035-08-07
- **Target enrollment:** 1800 (ESTIMATED)
- **Last updated:** 2026-04-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07441460

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07441460, "A Phase III Study of KN026 in Combination With HB1801 as Adjuvant Therapy for Resectable HER2-Positive Breast Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT07441460. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*